Cancer Research Meeting Calendar EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 67, 6360, July 1, 2007. doi: 10.1158/0008-5472.CAN-06-3012
© 2007 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Magnaghi-Jaulin, L.
Right arrow Articles by Jaulin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Magnaghi-Jaulin, L.
Right arrow Articles by Jaulin, C.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Histone Deacetylase Inhibitors Induce Premature Sister Chromatid Separation and Override the Mitotic Spindle Assembly Checkpoint

Laura Magnaghi-Jaulin, Grégory Eot-Houllier, Géraldine Fulcrand and Christian Jaulin

INSERM EMI 229, CRLC Val d'Aurelle-Paul Lamarque, and Université MONTPELLIER1, Montpellier, France

Requests for reprints: Christian Jaulin, INSERM EMI 229, CRLC Val d'Aurelle-Paul Lamarque, Parc Euromédecine, 34298 Montpellier Cedex 5, France. Phone: 33-46761-3751; Fax: 33-46761-3787; E-mail: cjaulin{at}valdorel.fnclcc.fr.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Histone deacetylase inhibitors (HDACI) are powerful antiproliferative drugs, and are currently undergoing clinical trials as antitumor agents. It would be valuable for both cancer therapy and our knowledge of basic cellular processes to understand the mechanisms by which HDACIs block cell proliferation. Most current models postulate that HDACIs allow the reexpression of tumor suppressor genes silenced in cancer cells. However, other mechanisms, distinct from transcription regulation, may participate in HDACI antiproliferative properties. We report that HDACI treatment induces premature sister chromatid separation in cells in which the mitotic spindle assembly checkpoint (SAC) has already been activated. This effect was transcription-independent. In addition, HDACI-treated mitotic cells displayed SAC inactivation characteristics, including anaphase-promoting complex/cyclosome target degradation, cyclin-dependent kinase 1 inactivation, histone H3 dephosphorylation, and loss of the SAC component MAD2 from the kinetochore. Thus, HDAC inhibition renders the SAC ineffective. Our findings help elucidate the molecular mechanisms of proliferative cell death induced by HDACI treatment and may allow new HDACI-based preclinical and clinical trial protocols to be redesigned so as to target mitosis. [Cancer Res 2007;67(13):6360–7]


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Histone deacetylase (HDAC) inhibitors (HDACI) exhibit antiproliferative activity against a variety of human cancers. They are currently undergoing clinical trials and the outlook is promising. However, the molecular basis of their antitumor properties remains poorly understood (1, 2). It was first suggested that HDAC inhibition induces the reexpression of silenced tumor suppressor genes by affecting the chromatin structure of their promoters (3). For example, treatment of cells with HDACI often induces the expression of the cyclin-dependent kinase (cdk) inhibitor p21WAF1/CIP1 in a p53-independent manner (4, 5). The expression of a number of genes other than cell cycle regulator genes is also altered by HDACI treatment: they include genes involved in the induction of apoptosis, the activation of the immune response, and the inhibition of angiogenesis (6). However, gene profiling studies showed that the expression of a surprisingly small fraction of genes is affected by HDACI treatments and it remains uncertain whether these particular genes are sufficient to drive cancer cells towards differentiation, apoptosis, or growth arrest pathways (7–10). Therefore, it has been suggested that nontranscriptional targets may be equally important for HDACI antitumor activity (11–13). One potential nontranscriptional target is the centromere/kinetochore structure. Indeed, low-dose trichostatin A (TSA) treatment destabilizes the higher-order structure of pericentric heterochromatin, and leads to HP1 spreading and centromere subnuclear localization (14). Pericentric heterochromatin plays an important role in centromere function, and HDACI treatments may lead to kinetochore defects and aberrant mitosis. Accordingly, several studies report that HDACI treatment increases chromosomal instability characterized by chromatin bridges, chromosome breaks, and segregation defects (14–16). These features suggest that the nontranscriptional targets of HDACI include mitosis and the mechanisms that regulate its accuracy. Segregation deficiency is a common characteristic of HDACI-treated cells and of mitotic spindle assembly checkpoint (SAC) defects. We therefore examined whether HDACIs can target the SAC.

The SAC is a cellular mechanism that ensures faithful sister chromatid segregation during mitosis by delaying anaphase until all kinetochores have been attached to spindle microtubules (17). A defect in this function results in unbalanced chromosome segregation, and consequently, aneuploid daughter cells. Unattached kinetochores generate an inhibitory signal acting on the anaphase-promoting complex/cyclosome (APC/C), a multiprotein complex whose ubiquitin ligase activity is required to target mitosis-specific factors (such as cyclin B1 and securin) to proteasome-dependent degradation. The attachment of the last free kinetochore abrogates the inhibitory signal and thus permits the transition from metaphase to anaphase and subsequent exit from mitosis. Inhibition of the SAC by mutation of its components, haploinsufficiency, or down-regulation of one of its elements results in premature sister chromatid separation (PSCS) and APC/C target degradation despite of SAC activation conditions (18–21). Furthermore, long-term total SAC inhibition is not viable. Null mutations of the SAC component MAD2 is lethal (22) and extended inhibition of SAC by RNA interference affecting key SAC elements leads to cell death within a few generations (23). The most likely explanation for this lethality is the accumulation of nonviable aneuploid cells due to premature anaphase entry. Consequently, because the cell toxicity resulting from SAC inhibition is expected to be restricted to proliferating cells, the SAC is a putative therapeutic target for anticancer treatments (24). However, the only SAC down-regulation techniques currently known are genetic and, in the foreseeable future, unsuitable for application to human therapy.

To determine whether HDACIs can be used as pharmacologic tools to target the SAC, we investigated mitosis exit in HDACI-treated cells in which the SAC was activated. We found that HDACI treatment triggers transcription-independent mitosis exit in a large proportion of prometaphase-arrested cells. We monitored SAC inhibition by detection of the major mitosis exit markers, including sister chromatid separation and proteasome-dependent degradation of key APC/C targets.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell culture and drug treatment. HeLa cells (human cervical carcinoma, obtained from American Type Culture Collection) were cultured in DMEM (Life Technologies) supplemented with L-glutamine, antibiotics, and 10% heat-decomplemented FCS (Invitrogen). In all experiments, growing cells were incubated in nocodazole (500 ng/mL) for 8 h and accumulated mitotic cells were harvested by mitotic shake-off (MSO) prior to other treatments. Nocodazole was permanently maintained in the medium when HDACIs or other drugs were added. For transcription inhibition and proteasome inhibition assays, {alpha}-amanitin (2 µg/mL) or MG132 (3 µmol/L) were added 1 h before TSA treatment; {alpha}-amanitin or MG132 were maintained in the culture medium after the addition of TSA. Unless otherwise stated, the TSA concentration was 200 ng/mL. All reagents were purchased from Sigma-Aldrich, except for MG132 (Biomol Int.).

Chromosome spreads. Metaphase spreads were done essentially as described (25) and DNA was stained with 4',6-diamidino-2-phenylindole (DAPI; 100 ng/mL) using Mowiol as the mounting medium. At least 500 cells were scored for each experimental point. All experiments were done at least in duplicate.

Immunoblotting. Cells were harvested, counted, lysed directly in Laemmli buffer and boiled for 5 min. Samples corresponding to 6 x 104 cells were separated by SDS-PAGE and transferred to nitrocellulose membranes (Hybond-C Extra, Amersham); the membranes were probed with monoclonal anti–cyclin B1 antibodies (Santa Cruz), polyclonal anti-securin antibodies (Zymed), or anti-actin antibodies (Sigma) according to standard procedures. Western Lighting Chemiluminescence Plus (Perkin-Elmer) was used to visualize binding, according to the instructions of the supplier.

Cdk1 kinase assays and immunoprecipitation. Cdk1 immunoprecipitation followed by cdk1 kinase assays were as previously described (26). Assays were analyzed by autoradiography, and kinase activity was determined using a Phosphoimager (BAS-5000, FUJI). Cdk1 immunoprecipitates were analyzed by immunoblotting using a monoclonal anti-cdk1 antibody (Santa Cruz).

Immunofluorescence microscopy. Chromosome spread slides (Fig. 6B) were washed twice in PBS for 10 min, incubated with 0.1% Triton X-100, washed thrice in PBS, blocked with 5% FCS, and stained with rabbit polyclonal anti-H3 serine 10 phosphorylated antibodies (UBI) overnight at 4°C. Goat anti-rabbit conjugated-FITC antibodies (Biosource International) were used for secondary staining for 1 h at room temperature. For whole cell immunofluorescence (Figs. 5B and 6A), cells were grown on polylysine-treated coverslips, fixed in 3% formaldehyde, washed in PBS, incubated for 15 min with 100 mmol/L of glycine (pH 7), permeabilized with 0.1% Triton X-100, washed in PBS, blocked with 5% FCS, and incubated with rabbit polyclonal anti-lamin A/C antibodies (Cell Signaling), human CREST serum (a kind gift from Dr. C. Johanet, Hôpital Saint-Antoine, Paris), or rabbit polyclonal anti-MAD2 antibodies (Covance). Goat anti-rabbit conjugated-FITC antibodies (Biosource International) and goat anti-human conjugated-TRITC antibodies (Jackson ImmunoResearch) were used as secondary antibodies. In all experiments, DNA was stained with DAPI (100 ng/mL) and Mowiol was used as the mounting medium. Samples were examined under an epifluorescence microscope (Leica DMRM).


Figure 6
View larger version (40K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. Loss of mitosis markers from chromosomes in nocodazole-arrested HeLa cells exposed to TSA. Top, experimental outline (see legend to Fig. 1). A, immunofluorescence microscopy showing DAPI, CREST, and MAD2 staining on nocodazole-arrested mitotic HeLa cells treated or not treated with TSA. B, chromosome spread stained with DAPI and with antihistone H3 phosphorylated on serine 10. Arrow, cell with a PSCS phenotype that has lost H3S10 phosphorylation.

 

Figure 5
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. Decreased cyclin B1–associated cdk1 kinase activity and nucleus formation in nocodazole-arrested mitotic HeLa cells following TSA treatment. Top, experimental outline (see legend to Fig. 1). A, cdk1 kinase activity against a histone H1 substrate from nocodazole-arrested mitotic HeLa cells treated with TSA, MG132, and TSA, or neither (nocodazole alone). Top, histone H1 phosphorylation by cdk1 kinase activity (H1 32P), Coomassie staining of the gel showing H1 recovery in the assay (H1 Total), and control immunoblot of immunoprecipitated cdk1 kinase (IP cdk1). Bottom, quantification of cdk1 kinase activity. Columns, means from four independent experiments; bars, SD. B, reformation of nuclear envelope induced by TSA. Immunofluorescence microscopy showing nocodazole-arrested mitotic HeLa cells treated or not treated with TSA for 16 h, in the persistent presence of nocodazole. DAPI staining (DNA) and lamin A/C immunostaining. N, nuclei; m, mitotic figure; ap, apoptotic cell. Nuclear envelope–positive cells are more frequent in the mitotic TSA-treated samples than in the controls.

 

   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Prometaphase-arrested cells undergo HDACI-induced PSCS in a transcription independent manner. In all experiments, mitotic SAC was activated by pretreatment with the microtubule-destabilizing agent nocodazole. Nocodazole treatment activates the SAC by preventing microtubule-kinetochore interaction. Once the SAC is activated, cells accumulate in prometaphase and, depending on the cell type and the nocodazole concentration, remain arrested between a few hours and several days. Under our culture conditions, >60% of HeLa cells were arrested in prometaphase following an 8-h nocodazole treatment and remained stably blocked in prometaphase for the following 24 h without significant mitosis exit or cell death. HeLa cells were treated with nocodazole for 8 h and mitosis-arrested cells were collected by MSO. Then, the cells were incubated with TSA, a powerful HDACI, for 16 h. Nocodazole was present in the culture medium during TSA treatment. A proportion of chromosome spreads from nocodazole/TSA–treated cells displayed a characteristic PSCS phenotype (Fig. 1A ): sister chromatids were no longer attached at the centromere and the constriction point was not visible anymore. In addition, despite the extended nocodazole treatment (which is known to overcondense metaphasic chromosomes), chromosome arms in nocodazole/TSA–treated cells displaying PSCS seemed to be longer and less tightly condensed than in the controls. This PSCS phenomenon, also called "precocious anaphase," was observed in ~25% of nocodazole/TSA–treated cells, and all chromosomes in any one cell displayed an identical phenotype. No PSCS was detected in control nocodazole-treated HeLa cells.


Figure 1
View larger version (52K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. TSA treatment induces both PSCS and partially decondensed chromosomes in nocodazole-arrested mitotic cells. Top, experimental outline. Cells were incubated with nocodazole for 8 h, and mitotic cells were collected by MSO and were incubated with nocodazole in the presence or absence of TSA for 16 h. A, chromosome spreads from control mitotic nocodazole (left) or nocodazole/TSA–treated (200 ng/mL, 16 h) HeLa cells (right). Brackets, incompletely condensed sister chromatids lying separated and adjacent to each other. B, the frequency of PSCS is TSA-dose dependent. Various doses of TSA (0, 80, 200, or 500 ng/mL) were added to nocodazole-arrested mitotic HeLa cells. C, increasing TSA dose decreases the mitotic index in nocodazole-arrested mitotic HeLa cells.

 
TSA-induced PSCS was dose-dependent (Fig. 1B). In addition, the mitotic index of control nocodazole-treated cells was >80%, whereas that of TSA-treated cells declined in a TSA dose-dependent manner to <40% (Fig. 1C). Cell viability was assessed by trypan blue exclusion and cell counting. Under these treatment conditions, a few apoptotic cells (condensed fragmented nuclei as depicted on Fig. 5B, cells labeled "ap") were detected although cell mortality was <5%. Therefore, specific mitotic cell mortality cannot account for the observed decrease in the mitotic index.

PSCS increase and mitotic index decrease induced by TSA were also observed in a human breast cancer cell line (MDA-MB-231) and in human primary fibroblasts and, thus, are not specific to the transformed HeLa cell line (Fig. 2 ).


Figure 2
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. The effect of TSA on other cells. Top, experimental outline (see legend to Fig. 1). A, TSA-induced PCSC in nocodazole-arrested MDA-MB-231 breast cancer cell line (MDA) and human untransformed fibroblasts (HDF). B, TSA treatment of nocodazole-arrested MDA-MB-231 and HDF cells results in mitotic index decrease. Columns, means from at least two independent experiments; bars, SD.

 
To determine if the effects described above were specific for TSA or are found with other HDACIs, nocodazole-treated cells were incubated with various different HDACIs belonging to three different classes (Fig. 3A ). Sodium butyrate and valproic acid are short-chain fatty acids, TSA is a hydroxamic acid and apicidin belongs to the cyclic tetrapeptide class of HDACIs (1). Sodium butyrate and apicidin induced PSCS (although to a lesser extent than TSA) but valproic acid did not (Fig. 3A, top); however, all HDACIs tested decreased the mitotic index of nocodazole-treated cells (Fig. 3A, bottom). This suggests that HDAC inhibition in SAC-activated mitotic cells causes abnormal mitosis exit.


Figure 3
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Different unrelated HDACIs cause PSCS and decrease the mitotic index. TSA-induced PSCS and the mitotic index decrease do not require transcription. Top, experimental outline (see legend to Fig. 1). A, PSCS frequency and decreased mitotic index in the presence of various HDACIs. Nocodazole-arrested mitotic HeLa cells were treated for 16 h with TSA (200 ng/mL), sodium butyrate (NaB; 100 mmol/L), apicidin (Api; 5 µg/mL), or valproic acid (VPA; 30 mmol/L). Columns, percentage of PSCS (top) and mitotic index (bottom) observed in chromosome spreads. B, TSA-induced PSCS frequency and decreased mitotic index do not involve transcription. Nocodazole-arrested mitotic HeLa cells were treated or not treated with 2 µg/mL of {alpha}-amanitin for 1 h, then treated with 200 ng/mL of TSA for 16 h, without removing the nocodazole or {alpha}-amanitin. Columns, percentage of PSCS (top) and mitotic index (bottom) observed in chromosome spreads. Columns, means from at least two independent experiments; bars, SD.

 
Although gene transcription in metaphase-arrested cells is almost completely silenced (27), it is possible that HDACI induced aberrant mitotic transcription. To determine whether the TSA-induced PSCS was due to the reactivation of transcription at loci normally silenced during mitosis, nocodazole-treated cells were incubated with {alpha}-amanitin (at a concentration known to completely inhibit transcription by RNA polymerase II) prior to TSA treatment (28). This inhibition of transcription had no effect on TSA-induced PSCS (Fig. 3B, top), or on the mitotic index (Fig. 3B, bottom). These results suggest that HDAC inhibition overrides the prometaphase block in mitotic SAC-activated cells in a transcription-independent manner.

Key targets of APC/C are degraded in a proteasome-dependent manner following TSA treatment. SAC activation inhibits the ubiquitin ligase complex APC/C. Activation of APC/C at the metaphase-anaphase transition leads to polyubiquitination of cyclin B1 and securin, such that they are targeted to a proteasome-dependent degradation pathway. These two proteins are believed to be the only essential APC/C targets (29). Under conditions of sustained SAC activation (i.e., nocodazole treatment), APC/C targets accumulate and reach a high stable concentration.

To determine whether APC/C activity was affected by TSA treatment, the stability of APC/C targets was assessed by Western blotting using anti-cyclin B1 and anti-securin antibodies as probes. Cyclin B1 accumulated, as expected, in nocodazole-treated cells (Fig. 4, lane 2 ). TSA treatment of nocodazole-arrested cells resulted in a sharp decrease in the abundance of cyclin B1 (lane 3). Pretreatment with the proteasome inhibitor MG132 prevented this TSA-induced decrease (lane 4). Similar results were obtained for securin. The amount of cyclin B1 or securin detected in TSA-treated cells was intermediate between those observed in untreated and nocodazole-treated cells. These data show that TSA treatment induces a proteasome-dependent degradation of major APC/C targets.


Figure 4
View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. HDAC inhibition by TSA in nocodazole-arrested mitotic HeLa cells induces proteasome-dependent degradation of APC/C target proteins. Top, experimental outline (see legend to Fig. 1). Immunoblot analysis of total cellular protein extract obtained from control untreated cycling HeLa cells (lane 1) and nocodazole-arrested mitotic HeLa cells (lanes 2–5), treated with 3 µmol/L of MG132 for 1 h (lanes 4 and 5), and then with 200 ng/mL of TSA for 16 h (lanes 3 and 4), without removing the nocodazole or MG132. Actin was used as an immunoblot loading control.

 
TSA treatment induces classical mitosis exit markers. Our data suggests that HDAC inhibition leads to SAC dysfunction. To confirm that prometaphase-arrested cells indeed exit mitosis in the presence of HDACI, we examined classical markers of mitosis exit including cdk1 inactivation, histone H3 serine 10 dephosphorylation, nuclear membrane reformation, and release of SAC components from the kinetochore.

To determine whether TSA-induced degradation of cyclin B1 led to a decrease of cdk1 activity, cdk1 was immunoprecipitated and its kinase activity was measured with histone H1 as a substrate. TSA treatment induced a substantial decrease in the cdk1 activity in nocodazole-treated cells, although the amounts of cdk1 protein recovered in the immunoprecipitates from treated and untreated samples were comparable (Fig. 5A ). Coomassie staining of the gel showed that reduced H1 phosphorylation signal following TSA treatment was not due to reduced amounts of histone H1 recovered in the assay (Fig. 5A, "H1 Total"). Proteasome inhibition in nocodazole/TSA–treated cells did not rescue the cdk1 activity (Fig. 5A), although the addition of MG132 blocked TSA-induced cyclin B1 degradation (Fig. 4). This can be explained by the finding that cdk1 and polyubiquitinated cyclin B1 were dissociated by a nonproteolytic function of the proteasome (30). Thus, in the presence of MG132, polyubiquitinated cyclin B1 is not degraded and can be detected by immunoblotting, but is not associated with cdk1. Quantification experiments showed that cdk1 activity was three times higher in control nocodazole-treated cells than in nocodazole/TSA–treated cells (Fig. 5A, bottom).

Mitotic index measurements (Fig. 1C) showed that TSA treatment was associated with more nuclei-like figures displaying decondensed chromatin but were unable to indicate whether a nuclear envelope was reformed around the chromatin. To resolve this question, nocodazole/TSA–treated cells and control (nocodazole alone) cells were immunolabeled for lamin A/C (Fig. 5B). Most TSA-treated nuclei-like figures were positive for lamin A/C, indicating that a nuclear envelope had reformed in these cells.

SAC inhibition and subsequent anaphase entry are characterized by the release of SAC components from the kinetochores. We examined kinetochore localization of MAD2, a major downstream SAC effector, by immunofluorescence. Kinetochores were labeled with a human CREST autoimmune serum, which recognizes the kinetochore proteins CENP-A, CENP-B, and CENP-C, whereas MAD2 was detected with a specific antibody. Characteristic CREST-positive kinetochore dots were observed in both control and nocodazole/TSA–treated mitotic cells, indicating that TSA treatment does not lead to major kinetochore damage, although MAD2 was found to be displaced from kinetochores in approximately one third of nocodazole/TSA–treated mitotic cells (Fig. 6A ). MAD2 antibodies failed to label chromosome spreads, so we could not determine whether the mitotic cells that had lost MAD2 from kinetochores were the same as those displaying PSCS. Nevertheless, the respective proportions of cells exhibiting these phenomena were similar enough to assume that this was indeed the case.

We also tested the loss of histone H3 serine 10 (H3S10) phosphorylation. During normal mitosis, H3S10 becomes phosphorylated in prophase and remains phosphorylated until early anaphase. In metaphase-arrested cells (SAC activated), this phosphorylation was maintained. Chromosome spreads from control (nocodazole alone) and nocodazole/TSA–treated cells were immunostained for H3S10 phosphorylation (Fig. 6B). All chromosome spreads from nocodazole-treated control cells were positive for H3S10 labeling. In contrast, in nocodazole/TSA–treated cells, chromosome spreads displaying a normal phenotype (i.e., attached sister chromatids) were labeled by the H3S10-specific antibody, whereas chromosome spreads displaying PSCS were negative for H3S10 labeling. Figure 6B shows one normal, H3S10-positive, spread and, within the same microscope field, a H3S10-negative spread displaying a TSA-induced PSCS (arrow). Loss of H3S10 phosphorylation following TSA treatment has been previously reported using immunoblot techniques (31). However, our chromosome spread immunostaining approach allowed us to show that cells which displayed reduced TSA-induced H3S10 phosphorylation were the same as those which displayed PSCS. This indicates that cells presenting a TSA-induced PSCS are engaged into exit from mitosis. Taken together, our findings show that HDAC inhibition renders the SAC ineffective.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Understanding the molecular mechanisms of the antiproliferative properties of HDACIs is a major issue both in terms of anticancer therapy and in our knowledge of basic cellular functions. We investigated the integrity of the mitotic SAC in cells treated with HDACIs and found that HDAC inhibition results in SAC being overridden.

Previous reports suggest a role for HDACs in SAC regulation but the various studies led to apparently contradictory conclusions. For example, it has been reported that HDAC inhibition in mitosis prevented sister chromatid centromere separation, suggesting that HDACIs trigger the SAC abnormally (15). In contrast, other authors reported that HDACIs induced a down-regulation of cyclin B1–dependent kinase activity (32), suggesting that HDACI treatment leads to checkpoint inhibition. Accordingly, Dowling et al. described premature mitosis exit, H3S10 dephosphorylation, and diminished BUBR1 kinetochore localization following TSA treatment (31). These results clearly plead in favor of the existence of a TSA-induced SAC defect. However, recent data show that a slow but continuous degradation of cyclin B induces an apparent mitosis exit in spite of the presence of a functional and active SAC (33). In this particular situation, other APC/C targets are not degraded and MAD2 and BUBR1 remain attached to kinetochores. With the noteworthy exception of BUBR1 partial loss from kinetochores, data reported in ref. (31) could be attributed to a TSA-induced cyclin B degradation alone. BUBR1 delocalization described in ref. (31) is incomplete, and thus, it is not clear whether the remaining kinetochore-bound BUBR1 was sufficient to maintain the SAC or not. Conflicting reports exist on the amount of BUBR1 required to activate the SAC. One study reported that 25% of the normal amount of BUBR1 led to SAC defects (34), although in another study, heterozygous mice expressing only 29% of the normal amount of BUBR1 showed no SAC malfunction (35). Therefore, although the data reported by Dowling et al. represent the strongest evidence of a TSA-induced SAC malfunction to date, one cannot formally exclude that TSA induced cyclin B depletion–like defects and diminished BUBR1 kinetochore localization without inactivating the SAC. The finding by Cimini et al. (15) that TSA treatment induces persistent sister chromatid cohesion in anaphase would support this hypothesis. Thus, the primary consequences of SAC inhibition being the activation of APC/C and the subsequent proteasome-dependent degradation of its only known essential targets: cyclin B and securin, it seems essential to examine sister chromatin cohesion and securin status in order to assess definitively whether or not SAC function is altered. Our results show that TSA treatment induces securin degradation and sister chromatid separation. Therefore, the abnormal persistent chromatid cohesion observed in ref. (15) following TSA treatment was more likely the consequence of a TSA-induced impaired chromatin topological organization (chromatid entanglement) rather than a failure to cleave cohesins.

We found that when nocodazole-treated cells (to induce SAC activation) were subsequently treated with TSA, 25% of the mitotic cells displayed a characteristic PSCS phenotype which resembles that observed when the SAC is inhibited by antibody injection (18), RNA interference (20, 21), or by genetic means (19). Sister chromatids that have separated prematurely are considered a hallmark of a defective checkpoint (19). We also showed that TSA treatment induced the proteasome-dependent degradation of cyclin B1 and securin, two essential APC/C targets. Finally, we monitored exit from mitosis by different and independent means including testing for loss of cdk1 activity, histone H3 serine 10 dephosphorylation, reformation of the nuclear envelope, and MAD2 release from kinetochores. All tests done indicated that TSA treatment induced exit from mitosis in SAC-activated cells. Thus, our results show that HDAC inhibition overrides the SAC.

In every experiment done, HDACI treatment induced PSCS in only part of the cell population. Immunostaining experiments in nocodazole/TSA–treated cells with an antibody specific for a hyperacetylated form of histone H3 showed that histone H3 was hyperacetylated in all cells, ruling out the possibility that TSA did not act on a particular cell subpopulation (data not shown). However, this "partial" effect is consistent with the finding that TSA treatment led to only partial proteasome degradation of APC/C key targets. Although the reason for this heterogeneous response is not clear, a similarly incomplete response has also been observed in other SAC inhibition studies. For example, MAD2 knockdown in HeLa and HaCat cells induces PCSC in ~50% of the cells (20). Similarly, mutations of the gene encoding the SAC component BUBR1 in the mosaic variegated aneuploidy syndrome (36) leads to PSCS in only a fraction of the cells (37).

Not all HDACI were as effective in inducing PSCS. TSA was the best inducer, sodium butyrate and apicidin were intermediate, and valproic acid did not induce PSCS. However, all HDACI induced a similar decrease in the mitotic index in nocodazole-treated cells. This apparent discrepancy may be due to the differences in the spectra of action of these drugs. Although little is known about the potential for each drug to inhibit a given subset of HDACs, TSA is one of the most potent HDACIs and is believed to act on both class I and class II HDACs. Thus, we propose that at least two distinct HDACs are required in mitosis: one necessary to maintain the SAC and sensitive to all the drugs tested, and the other required for anaphase progression and sensitive to TSA but insensitive to valproic acid (and partially sensitive to the two other drugs tested). Under this hypothesis, nocodazole/TSA–treated cells escape SAC activation, but a proportion remains blocked in anaphase, allowing the observation of PSCS. Conversely, nocodazole/valproic acid–treated cells would exit mitosis without pausing in anaphase. In this case, PSCS would not be observed but the mitotic index would decrease, in accordance with our observations.

In addition to PSCS, TSA treatment led to partial decondensation of mitotic chromosomes. This finding was restricted to cells displaying PSCS suggesting that the observed decondensation is a consequence of mitosis exit rather than a direct effect of chromatin hyperacetylation. Similar chromosome morphologic changes have been observed in HeLa and HaCat cells in which the key SAC component MAD2 has been knocked down (20). Thus, this incomplete decondensation phenotype is likely to be a direct consequence of TSA-induced SAC overriding.

The precise nature of the antiproliferative mechanism(s) of HDACIs remains a subject of debate. Sustained SAC inhibition leads to the death of proliferative cells within a few generations (23) and our results show that HDAC inhibition results in SAC inhibition making HDACIs the only clinically validated pharmacologic SAC inhibitors known thus far. We propose that this SAC-inhibiting activity may contribute to the antiproliferative properties of HDACIs. Histone acetylation is involved in transcription, so it is plausible that HDAC inhibition leads to the reexpression of antiproliferative genes silenced in tumor cells. However, a number of nonhistone proteins are regulated by acetylation and the possibility of an HDACI antiproliferative mechanism independent from transcription has emerged (11–13). Our results show that HDACI-driven SAC inhibition is transcription-independent, and thus, raise the possibility that the targets of HDACIs in anticancer therapy could be, at least in part, nontranscriptional.


   Acknowledgments
 
Grant support: Association pour la Recherche sur le Cancer (grant no. 4466), Ligue Contre le Cancer (Comités Départementaux de l'Hérault and de l'Aveyron and Comité Régional du Languedoc-Roussillon), and GEFLUC (Languedoc-Roussillon). G. Eot-Houllier is supported by a Ligue Nationale Contre le Cancer fellowship. G. Fulcrand is supported by a Ligue Régionale Contre le Cancer Research Ph.D. scholarship (Comité du Languedoc Roussillon). L. Magnaghi-Jaulin is an investigator of the Centre National de la Recherche Scientifique.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank C. Johanet and J. Piette for the gift of reagents and J.M. Vanacker, J.M. Brondello, and J. Piette for discussions and critical reading of the manuscript.

Received 8/14/06. Revised 2/26/07. Accepted 4/19/07.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37–50.[CrossRef][Medline]
  2. Carey N, La Thangue NB. Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol 2006;6:369–75.[CrossRef][Medline]
  3. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194–202.[CrossRef][Medline]
  4. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000;97:10014–9.[Abstract/Free Full Text]
  5. Rocchi P, Tonelli R, Camerin C, et al. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 2005;13:1139–44.[Medline]
  6. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287–99.[CrossRef][Medline]
  7. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000;60:4561–72.[Abstract/Free Full Text]
  8. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2:151–63.[Abstract/Free Full Text]
  9. Chiba T, Yokosuka O, Fukai K, et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology 2004;66:481–91.[CrossRef][Medline]
  10. Lee HS, Park MH, Yang S, et al. Gene expression analysis in human gastric cancer cell line treated with trichostatin A and S-adenosyl-L-homocysteine using cDNA microarray. Biol Pharm Bull 2004;27:1497–503.[CrossRef][Medline]
  11. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4:13–8.[Medline]
  12. Marks PA, Richon VM, Miller T. Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004;91:137–68.[CrossRef][Medline]
  13. Taddei A, Roche D, Bickmore WA, Almouzni G. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 2005;6:520–4.[CrossRef][Medline]
  14. Taddei A, Maison C, Roche D, Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 2001;3:114–20.[CrossRef][Medline]
  15. Cimini D, Mattiuzzo M, Torosantucci L, Degrassi F. Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol Biol Cell 2003;14:3821–33.[Abstract/Free Full Text]
  16. Xu WS, Perez G, Ngo L, Gui CY, Marks PA. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 2005;65:7832–9.[Abstract/Free Full Text]
  17. Cleveland DW, Mao Y, Sullivan KF. Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell 2003;112:407–21.[CrossRef][Medline]
  18. Gorbsky GJ, Chen RH, Murray AW. Microinjection of antibody to Mad2 protein into mammalian cells in mitosis induces premature anaphase. J Cell Biol 1998;141:1193–205.[Abstract/Free Full Text]
  19. Michel LS, Liberal V, Chatterjee A, et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001;409:355–9.[CrossRef][Medline]
  20. Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A 2004;101:4459–64.[Abstract/Free Full Text]
  21. Kienitz A, Vogel C, Morales I, Muller R, Bastians H. Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene 2005;24:4301–10.[CrossRef][Medline]
  22. Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 2000;101:635–45.[CrossRef][Medline]
  23. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 2004;101:8699–704.[Abstract/Free Full Text]
  24. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5:773–85.[CrossRef][Medline]
  25. Verma R, Babu A. Human chromosomes: principles and techniques. New York: McGraw Hill; 1995.
  26. Bayart E, Grigorieva O, Leibovitch S, Onclercq-Delic R, Amor-Gueret M. A major role for mitotic CDC2 kinase inactivation in the establishment of the mitotic DNA damage checkpoint. Cancer Res 2004;64:8954–9.[Abstract/Free Full Text]
  27. Gottesfeld JM, Forbes DJ. Mitotic repression of the transcriptional machinery. Trends Biochem Sci 1997;22:197–202.[CrossRef][Medline]
  28. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051–60.[CrossRef][Medline]
  29. Thornton BR, Toczyski DP. Securin and B-cyclin/CDK are the only essential targets of the APC. Nat Cell Biol 2003;5:1090–4.[CrossRef][Medline]
  30. Nishiyama A, Tachibana K, Igarashi Y, et al. A nonproteolytic function of the proteasome is required for the dissociation of Cdc2 and cyclin B at the end of M phase. Genes Dev 2000;14:2344–57.[Abstract/Free Full Text]
  31. Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD. Mitotic spindle checkpoint inactivation by trichostatin A defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther 2005;4:197–206.[Medline]
  32. Warrener R, Beamish H, Burgess A, et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 2003;17:1550–2.[Abstract/Free Full Text]
  33. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006;16:1194–200.[CrossRef][Medline]
  34. Dai W, Wang Q, Liu T, et al. Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res 2004;64:440–5.[Abstract/Free Full Text]
  35. Baker DJ, Jeganathan KB, Cameron JD, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet 2006;36:744–9.[CrossRef]
  36. Hanks S, Coleman K, Reid S, et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet 2004;36:1159–61.[CrossRef][Medline]
  37. Kajii T, Ikeuchi T, Yang ZQ, et al. Cancer-prone syndrome of mosaic variegated aneuploidy and total premature chromatid separation: report of five infants. Am J Med Genet 2001;104:57–64.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
B. Cadot, M. Brunetti, S. Coppari, S. Fedeli, E. de Rinaldis, C. D. Russo, P. Gallinari, R. De Francesco, C. Steinkuhler, and G. Filocamo
Loss of Histone Deacetylase 4 Causes Segregation Defects during Mitosis of p53-Deficient Human Tumor Cells
Cancer Res., August 1, 2009; 69(15): 6074 - 6082.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Haberland, A. Johnson, M. H. Mokalled, R. L. Montgomery, and E. N. Olson
Genetic dissection of histone deacetylase requirement in tumor cells
PNAS, May 12, 2009; 106(19): 7751 - 7755.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
G. Eot-Houllier, G. Fulcrand, Y. Watanabe, L. Magnaghi-Jaulin, and C. Jaulin
Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesion
Genes & Dev., October 1, 2008; 22(19): 2639 - 2644.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Dai, S. Chen, C. A. Venditti, X.-Y. Pei, T. K. Nguyen, P. Dent, and S. Grant
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
Blood, August 1, 2008; 112(3): 793 - 804.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Hadnagy, R. Beaulieu, and D. Balicki
Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics
Mol. Cancer Ther., April 1, 2008; 7(4): 740 - 748.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Magnaghi-Jaulin, L.
Right arrow Articles by Jaulin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Magnaghi-Jaulin, L.
Right arrow Articles by Jaulin, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online